MRSN · As filed with the SEC
Mersana Therapeutics income statement, by fiscal year
The statement as Mersana Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Loss · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Collaboration revenue | 40,497 | 36,855 | 26,581 | 43 |
| Operating expenses: | ||||
| Research and development expense: | 73,020 | 148,269 | 173,385 | 132,013 |
| General and administrative expense | 40,813 | 59,543 | 56,963 | 36,888 |
| Restructuring expenses | 0 | 8,713 | — | — |
| Total operating expenses | 113,833 | 216,525 | 230,348 | 168,901 |
| Other income (expense): | ||||
| Interest income | 8,436 | 12,073 | 2,883 | 65 |
| Interest expense | — | (4,073) | (3,328) | (1,267) |
| Interest expense | (3,874) | — | — | — |
| Total other income (expense), net | 4,562 | 8,000 | (445) | (1,202) |
| Loss before income taxes | (68,774) | — | — | — |
| Income tax expense | (418) | — | — | — |
| Net loss | (69,192) | (171,670) | (204,212) | (170,060) |
| Other comprehensive loss: | ||||
| Unrealized (loss) gain on marketable securities | (1) | 163 | (152) | 0 |
| Comprehensive loss | (69,193) | (171,507) | (204,364) | (170,060) |
| Net loss attributable to common stockholders - basic | (69,192) | (171,670) | (204,212) | (170,060) |
| Net loss attributable to common stockholders - diluted | (69,192) | (171,670) | (204,212) | (170,060) |
| Net loss per share attributable to common stockholders — basic (in dollars per share) | (0.56) | (1.48) | (2.18) | (2.41) |
| Net loss per share attributable to common stockholders — diluted (in dollars per share) | (0.56) | (1.48) | (2.18) | (2.41) |
| Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — basic (in shares) | 122,539,598 | 116,112,891 | 93,654,243 | 70,580,949 |
| Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — diluted (in shares) | 122,539,598 | 116,112,891 | 93,654,243 | 70,580,949 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.